Newton, MA, United States of America

Jeffrey Behrens

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 2.7

ph-index = 2

Forward Citations = 32(Granted Patents)


Location History:

  • Newton, MA (US) (2018 - 2022)
  • Newton, TV (2023)

Company Filing History:


Years Active: 2018-2023

Loading Chart...
Loading Chart...
4 patents (USPTO):

Title: Inventor Profile: Jeffrey Behrens

Introduction

Jeffrey Behrens, based in Newton, MA, is an accomplished inventor with a focus on innovative therapeutic solutions. With a total of four patents to his name, his work primarily centers around glycan-interacting compounds that hold promise in treating various human diseases, including cancer.

Latest Patents

Among his latest patents is a groundbreaking invention entitled "Glycan-interacting compounds and methods of use." This patent presents glycan-interacting antibodies and outlines methods for their production, aimed at the treatment and prevention of diseases such as cancer. These antibodies consist of monoclonal antibodies, derivatives, and fragments, as well as compositions and kits that encompass them. Additionally, another notable patent also titled "Glycan-interacting compounds and methods of use" introduces antibodies containing T cell-interacting regions and/or glycan-interacting regions. It discusses bispecific antibodies capable of recruiting T cells to cancer cells, including those expressing sialyl Tn (STn). This patent further explores methodologies for targeting and killing cells using these innovative antibodies, highlighting the potential impact on cancer therapies.

Career Highlights

Throughout his career, Jeffrey Behrens has made significant contributions while working for notable companies such as Seagen Inc. and Siamab Therapeutics, Inc. His dedication to advancing medical research has been reflected in his exceptional patent portfolio.

Collaborations

Jeffrey has collaborated with several esteemed colleagues in the field, including Julie DeSander and Alexey Alexandrovich Lugovskoy. These partnerships have strengthened his research efforts and contributed to the advancement of innovative solutions in healthcare.

Conclusion

In summary, Jeffrey Behrens stands out as a prominent inventor whose work on glycan-interacting antibodies is paving the way for new treatment modalities, particularly in cancer therapy. His continued innovation is expected to have a lasting impact on the medical field, marking him as a noteworthy figure in the realm of invention and patenting.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…